Bullish Price Target By Chardan Capital Stirs Up Traders

Bullish Price Target By Chardan Capital Stirs Up Traders

By: Dylan Sikes – AllPennyStocks.com News

Tuesday, September 13, 2022

A New Jersey-based biotech company turned the heads of both investors and apparently analysts after it was announced that Chardan Capital started the company at a ‘Buy’ with a $10 price target. Seeing that Outlook Therapeutics Inc. (Nasdaq:OTLK) closed yesterday at just $1.12/share, naturally traders got excited on this potential upside.

Background: Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.

As previously mentioned, traders were excited to get their hands on shares of this small cap following the press release as they pushed the price briefly up to $1.225/share (+9.38%) at the session high. 


Copyright © 2022 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Other Penny Stock Movers

Shares on the Rise Following Partnership News With Major Potato Chip Brand
Re-Classification of Marijuana Sends Shares of Cannabis Operator on a Tear
Biotech Soars on Research Collaboration And License Agreement Release
Most Popular
FREE Newsletter


Back to Top